Search
simufilam
Indications:
- investigational agent for treatment of mild-to-moderate Alzheimer's disease
Dosage:
- 100 mg PO BID
Mechanism of action:
- restores altered filamin A
Clinical trial:
- NIH-funded phase 2 trial: [1]
- improvement of 10% in ADAS-Cog score after 6 months
- improvement of 29% in Neuropsychiatric Inventory after 6 months [1]
General
pharmaceutical agents for treatment of Alzheimer's disease (Alzheimer's agent)
References
- Hoffman M
Simufilam Shows Promise Improving Cognition, Behavior in Alzheimer Disease Patients.
Doximity: HCPLive. Feb 5, 2021
https://www.hcplive.com/view/simufilam-shows-promise-improving-cognition-behavior-alzheimer-disease-patients
- Mandavilli A
Scientists Question Data Behind and Experimental Alzheimer's Drug.
New York Times. April 18, 2022
https://www.nytimes.com/2022/04/18/health/alzheimers-cassava-simufilam.html